ClinicalTrials.gg

TargetBeta

ROS1

ROS proto-oncogene 1, receptor tyrosine kinase · also MCF3, ROS, c-ros-1 · Fibronectin type III domain containing

8 programs in company-led studies act on ROS1, from 7 companies: 4 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
CrizotinibrulePfizerphase 4312 runningALK, EML4, MET, MST1R, NPM1ChEMBL
taletrectinibruleNuvation Biophase 3115 runningNTRK1, NTRK2, NTRK3NCIt
repotrectinibruleBristol-Myers Squibbphase 393 runningALK, CD74, NTRK1, NTRK2, NTRK3, PTK2, SDC4, SRCNCIt
FudotinibruleGuangzhou JOYO Pharmaphase 333 running–NCIt
Cross-over to JYP0322ruleGuangzhou JOYO Pharmaphase 311 running–the studies' text
Radiosensitizer VS-101ruleVSPharmTechphase 221 running–NCIt
ROS1/NTRK Inhibitor ANS03ruleAvistone Biotechnologyphase 111 running–NCIt
SIM0518ruleSimcere Pharmaceutical Groupphase 111 runningALKthe studies' text

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.